C. pneumoniae causes approximately 10% of community-acquired pneumonia and 5% of pharyngitis, bronchitis, and sinusitis. The clinical symptoms of C. pneumoniae pulmonary infections are similar to those caused by other respiratory pathogens, except for a few distinguishing features. Antibodies against C. pneumoniae are rare in children under the age of 5, except in developing and tropical countries. Antibody prevalence increases rapidly at ages 5 to 14, reaches 50% at the age of 20, and continues to increase slowly to 70% to 80% at ages 60 to 70.
The SeroCP™ product line is a well-known and established ELISA based assay for qualitative detection of antibodies to Chlamydia pneumoniae in human serum. Since their release, the kits have been extensively used in routine diagnosis and research studies.
The assay uses highly purified C. pneumoniae (TW-183) elementary bodies as antigens.
|Catalog No||Product name||Tests/kit||Approvals|
|A191-01||SeroCP™ IgG||96||CE 0483|
|A192-01||SeroCP™ IgM||96||CE 0483|
|A193-01||SeroCP™ IgA||96||CE 0483|